Skip to main content
Erschienen in: Health and Quality of Life Outcomes 1/2020

Open Access 01.12.2020 | Research

Evaluating prevalence of depression, anxiety and hopelessness in patients with Vitiligo on an Iranian population

verfasst von: Nasrin Hamidizadeh, Sara Ranjbar, Ahmad Ghanizadeh, Mohammad Mahdi Parvizi, Peyman Jafari, Farhad Handjani

Erschienen in: Health and Quality of Life Outcomes | Ausgabe 1/2020

Abstract

Introduction

Vitiligo is caused by partial or complete destruction of melanocytes in the affected skin area and influences the patient’s quality of life. Besides physical involvement, vitiligo patients experience a high level of stress. Depression and Anxiety are common psychiatric disorders in vitiligo patients.

Aim

This study, as the first study, evaluates hopelessness, anxiety, depression and general health of vitiligo patients in comparison with normal controls in an Iranian population.

Method

Hundred patients with vitiligo and hundred healthy controls were examined. General health, depression, hopelessness and anxiety were evaluated based on general health questionnaire. Anxiety, depression and hopelessness levels were analyzed using Chi–Square, and the mean value of general health was evaluated through t-test.

Results

The results showed that anxiety and hopelessness levels were significantly higher in vitiligo patients than those who are in healthy controls. This significant difference refers to high levels of anxiety and hopelessness among women with vitiligo.
It was also found that the single patients were more anxious, hopeless and depressive, while the married patients were only more anxious and hopeless than those who are in the control group, respectively.
General health of patients was significantly worse than in healthy controls. The low level of general health in patients was related to poorer level of general health among women with vitiligo.

Conclusion

It seems that women with vitiligo are more mentally stressed than men with vitiligo. Both singles and married vitiligo patients suffer from anxiety and hopelessness.
Hinweise
In this article, we reported the hopelessness, anxiety, depression, and general health of vitiligo patients in comparison with controls, to emphasize the mental problems of patients more. We noticed that women with vitiligo are more anxious and hopeless than men with vitiligo. Both married and single patients suffer from anxiety and hopelessness.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
BAI
Beck Anxiety Inventory
BDI
Beck’s Depression Inventory
BHS
Beck Hopelessness Scale
DLQI
Dermatology Life Quality Index
GHQ
General Health Questionnaire
IBM
International Business Machines
NY
New York
SD
Standard deviation
USA
United States of America

Introduction

Vitiligo is a chronic systemic disease which is characterized by hypopigmented macules and is caused by partial or complete destruction of melanocytes in the affected skin [13]. However, the exact cause of vitiligo is unknown; evidence suggests that various factors such as autoimmune, genetic and environmental factors are involved in the development of this disease. It affects 0.5–2% of the population worldwide regardless of race and gender [4, 5]. Women and men are equally affected by the vitiligo [6]. Although it can initiate at any time [7, 8], the initiation in 50% of the people is before 20 years [9]. Depending on how soon it starts, more skin will be damaged. Low prevalence of vitiligo is observed in Scandinavian countries while Asian, especially Indians and Middle Eastern are at greater risk [10]. It should be noted that vitiligo is usually asymptomatic; it does not shorten the patient’s life time and does not reduce physical activity [11, 12]. However, it results in several limitations such as regular visits for PUVA/narrow band UVB therapy, immunosuppressive therapies and risk of carcinogenesis with phototherapy.
Although vitiligo is not contagious, its effect on quality of life is related to psychological problems such as low self-esteem, embarrassment, negative effect on sexual relations, social isolation and experiencing vitiligo-related discrimination [1315]. Therefore, it becomes a barrier for seeking job and marriage; and social stigma and suicidal ideation have been also reported [16].
Vitiligo patients experience a high level of stress and psychiatric disorders in addition to physical involvement. Depression, anxiety, suicidal thoughts, suicidal attempts, embarrassment, social problems, discomfort, cognitive impairment, embarrassment, and physical limitation were reported in vitiligo patients [17, 18]. For this reason, vitiligo influences the patients’ quality of life; so, related psychiatric disabilities should not be underestimated [19].
Furthermore, the prevalence of depression has increased in Europe, Asia, Africa, and the Middle East in the recent years [20].
The present study evaluated hopelessness, anxiety, depression and general health of vitiligo patients who were attended in the phototherapy center at Faghihi Hospital. Meanwhile, considering the fact that vitiligo causes and related psychological disorders vary in different societies; psychological problems of patients with vitiligo were investigated in Shiraz.
For this purpose, general health, depression, hopelessness and patients’ anxiety were evaluated based on General Health Questionnaire-28 (GHQ-28) [21], Beck’s Depression Inventory [22], Beck Hopelessness Scale [23] and Beck Anxiety Inventory [24], respectively.

Method

This study was conducted at Molecular Dermatology Research Center which is affiliated to Shiraz University of Medical Sciences and Dermatology Clinic of Faghihi Hospital in Shiraz during one and a half year.
Vitiligo patients, who referred dermatology clinic and were being treated with phototherapy, were randomly allocated to case and control group based on black permutation design.
All patients of both genders, who were at least 18 years old, without any serious mental and physical disability, and those who consented to participate were enrolled in this study [17]. The sample size was estimated based on the mean score (standard deviation) of Beck’s depression inventory. The sample sizes was calculated according to previous studies between vitiligo patients [25] and healthy subjects (control group), respectively [26, 27]. Finally, 100 patients and 100 healthy controls were enrolled in the study. Based on error rate of type I and according to formula: N = 4 \( {\sigma}^2{\left(z\frac{a}{2}+ z\beta \right)}^2/{\left(\mu -{\mu}_2\right)}^2 \), α = 0.05, β = 0.2, power (1-β) = 80%, \( \raisebox{1ex}{${\mu}_{1-}{\mu}_2$}\!\left/ \!\raisebox{-1ex}{$\sigma $}\right.=\raisebox{1ex}{$1$}\!\left/ \!\raisebox{-1ex}{$2.5$}\right.=0.4. \)
Data were collected, using Beck’s Depression Inventory (BDI), Beck Hopelessness Scale (BHS), Beck Anxiety Inventory (BAI), and General Health Questionnaire (GHQ 28) after consulting with a psychology professor.
Validity and reliability of these questionnaires were evaluated in the relevant studies [2830]. Written informed consent was obtained from each participant and then, patient’s information forms and the questionnaires were completed by each patient after the disease confirmation by a dermatologist.
Beck’s Depression Inventory includes 21 questions, which evaluates the feelings of sadness, guilt, lack of interest, social isolation and suicidal ideation. Beck Hopelessness scale contains 20 statements, which measures negative attitudes or pessimism about the future, life prospect, achieving his/her desires or trusting the future.
Beck’s Anxiety Inventory contains 21 questions which measures anxiety, difficulty relaxing, nervous tension, agitation and restlessness during the past week. General health was also measured through a General Health Questionnaire including 21 questions, which asks respondents to report how they felt during the last 4 weeks on a range of symptoms including somatic symptoms, anxiety, insomnia, social dysfunction and severe depression. Patient demographic characteristics such as age, age of onset, gender, hereditary disease, comorbidities, disease-related involvement of the body surface, type of treatment and marital status were added to the questionnaires.
Statistical analysis was done using SPSS statistical software, version 18 (IBM, Armonk, NY, USA). The levels of anxiety, depression and hopelessness were measured using Chi–Square; the mean value of general health was evaluated through t-test and correlation coefficient was calculated using Spearman’s rank correlation coefficient. In all analytical tests, p value more than 0.5 was considered significant.

Results

Generally, 100 vitiligo patients and 100 healthy controls (as the control group) participated in this study, among which 134 were female and 66 male. The mean age of the patients and control group was 34.50 ± 12.225 and 37.300 ± 10.209 years, respectively, which was not significantly different (Table 1).
Table 1
Shows demographic characteristics of vitiligo and control group
 
n
Age (Mean ± SD)
p – value
Case
100
34.50 ± 12.225
0.081
Control
100
37.30 ± 10.209
Sex
 Case
  Female
69
34.22 ± 11.697
0.732
  Male
31
35.13 ± 13.515
 Control
  Female
65
36.23 ± 9.548
0.160
  Male
35
39.26 ± 11.200
Case
 Age of onset of vitiligo
  Female
69
22.94 ± 14.396
0.373
  Male
31
25.61 ± 12.339
 Duration of disease
  Female
69
11.28 ± 10.222
0.425
  Male
31
9.52 ± 10.013
Marital status (missing = 5)
 Married
  Case
56
39.02 ± 11.298
0.565
  Control
53
40.13 ± 8.614
 Single
  Case
42
28.10 ± 10.164
0.075
  Control
39
32.03 ± 9.413
 Widow
  Case
1
59
0.445
  Control
4
50.75 ± 8.421
Family history of vitiligo
 Female
22
32.50 ± 11.300
0.445
 Male
7
36.71 ± 16.070
The results showed that all three variables (hopelessness, anxiety and depression) had a positive and significant relationship with the disease duration. Age had negative relationship with hopelessness, anxiety and depression. It was significantly related to levels of hopelessness and depression, but it had not significant relationship with the level of anxiety (Table 2).
Table 2
Shows the correlation between depression, anxiety and hopeless levels with age A: in case group and B: in control group, and C: shows correlation between depression, anxiety and hopeless levels with duration of disease in vitiligo group
 
Correlation Coefficient
p-value
A: Case (n = 100)
 Age
  Depression
- 0.255
0.010
  Anxiety
- 0.147
0.150
  Hopeless
- 0.243
0.015
B: Control (n = 100)
 Age
  Depression
0.051
0.619
  Anxiety
0.026
0.801
  Hopeless
- 0.011
0.911
C: Case (n = 100)
 Duration of illness
  Depression
0.194
0.053
  Anxiety
0.293
0.003
  Hopeless
0.216
0.031
The levels of hopelessness, anxiety and depression were also measured in both patient and healthy controls based on gender. The results also showed that the patients were significantly more anxious and hopeless compared to the healthy controls while there was no difference in the level of depression between the patients and healthy controls. On the other hand, the women with vitiligo were significantly more anxious and hopeless than men with vitiligo (Tables 3 and 4).
Table 3
Show the prevalence and severity of depression, anxiety and hopelessness in the case and control group
 
Case
Control
p-value
Severity of depression
 Minimal
53 (53.0%)
60 (60%)
0.157
 Mild
19 (19.0%)
25 (25%)
 Moderate
16 (16.0%)
9 (9%)
 Severe
12 (12.0%)
6 (6%)
Severity of anxiety
 Minimal
32 (32. 7%)
49 (49.5%)
0.015
 Mild
27 (27.6%)
30 (30.3%)
 Moderate
25 (25.5%)
15 (15.2%)
 Severe
14 (14.3%)
5 (5.1%)
Severity of hopelessness
 Minimal
40 (40.0%)
48 (48.5%)
0.006
 Mild
34 (34%)
42 (42.4%)
 Moderate
18 (18.0%)
9 (9.1%)
 Severe
8 (8.0%)
0 (0%)
Table 4
Shows the prevalence and severity of depression, anxiety and hopelessness in women and men in the case and control group
 
Women
Men
Case
Control
p-value
Case
Control
p-value
Severity of depression
 Minimal
36 (52.2%)
39 (60.0%)
0.203
17 (54.8%)
21 (60.0%)
0.698
 Mild
12 (17.4%)
16 (24.6%)
7 (22.6%)
9 (25.7%)
 Moderate
12 (17.4%)
5 (7.7%)
4 (12.9%)
4 (11.4%)
 Severe
9 (13.0%)
5 (7.7%)
3 (9.7%)
1 (2.9%)
Severity of anxiety
 Minimal
15 (22.4%)
34 (53.1%)
0.002
17 (54.8%)
15 (42.9%)
0.354
 Mild
21 (31.3%)
17 (26.6%)
6 (19.4%)
13 (37.1%)
 Moderate
21 (31.3%)
10 (15.6%)
4 (12.9%)
5 (14.3%)
 Severe
10 (14.9%)
3 (4.7%)
4 (12.9%)
2 (5.7%)
Severity of hopelessness
 Minimal
26 (37.7%)
36 (56.3%)
0.021
14 (45.2%)
12 (34.3%)
0.093
 Mild
24 (34.8%)
22 (34.4%)
10 (32.3%)
20 (57.1%)
 Moderate
14 (20.3%)
6 (9.4%)
4 (12.9%)
3 (8.6%)
 Severe
5 (7.2%)
0 (0.0%)
3 (9.7%)
0 (0.0%)
Married patients were more anxious and hopeless based on their levels of hopelessness, anxiety and depression in comparison with the healthy control. The results of this study also showed that depression, anxiety and hopelessness levels of single patients were higher than the single subjects in the healthy controls. There was no significant difference in the levels of depression, anxiety and hopelessness between married and single vitiligo patients (Table 5).
Table 5
Shows the prevalence and severity of depression, anxiety and hopelessness in married and single patients in the case and control group
 
Married
Single
Case
Control
p-value
Case
Control
p-value
Severity of depression
 Minimal
35 (62.5%)
43 (81.1%)
0.137*
17 (40.5%)
14 (35.9%)
0.033*
 Mild
8 (14.3%)
2 (3.8%)
10 (23.8%)
20 (51.3%)
 Moderate
8 (14.3%)
5 (9.4%)
8 (19.0%)
2 (5.1%)
 Severe
5 (8.9%)
3 (5.7%)
7 (16.7%)
3 (7.7%)
Severity of anxiety
 Minimal
21 (38.9%)
33 (62.3%)
0.017*
10 (23.8%)
12 (31.6%)
0.008*
 Mild
15 (27.8%)
7 (13.2%)
12 (28.6%)
21 (55.3%)
 Moderate
9 (16.7%)
11 (20.8%)
15 (35.7%)
3 (7.9%)
 Severe
9 (16.7%)
2 (3.8%)
5 (11.9%)
2 (5.3%)
Severity of hopelessness
 Minimal
24 (42.9%)
34 (65.4%)
0.039*
15 (35.7%)
10 (25.6%)
0.040*
 Mild
18 (32.1%)
14 (26.9%)
15 (35.7%)
24 (61.5%)
 Moderate
11 (19.6%)
4 (7.7%)
7 (16.7%)
5 (12.8%)
 Severe
3 (5.4%)
0 (0.0%)
5 (11.9%)
0 (0.0%)
Regarding to the vitiligo-related involvement of the body surface, women whose hands were affected, and married patients with facial, arm, and hand involvement were significantly more anxious. Also, married patients whose genital areas were involved and single patients whose head/neck and trunk areas were involved were significantly more depressed (data was not shown).
Comparing the results of general health in patients with those of the control group showed that patients had significantly poorer general health than the healthy controls. Also, the results showed that women with vitiligo had poorer general health compared to women in the control group. However, the general health of men who suffer from vitiligo was not significantly different compared to the healthy men. There was no significant difference between women and men in relation to general health in patients and in controls, respectively (Table 6). Also, vitiligo involves body area which did not affect general health status (data not shown).
Table 6
shows GHQ positive and GHQ negative in the vitiligo group in comparison with the controls
 
n
GHQa(Mean ± SD)
p-value
GHQ -b n (%)
GHQ + c n (%)
p-value
Case
99
26.46 ± 15.183
0.036
50 (50.5)
49 (49.5)
0.018
Control
100
22.12 ± 13.852
67 (67.0)
33 (33.0)
Case
 Women
68
27.74 ± 15.554
0.219
33 (48.5)
35 (51.5)
0.666
 Men
31
23.68 ± 14.181
17 (54.8)
14 (45.2)
Control
 Woman
65
20.35 ± 13.008
0.082
45 (69.2)
20 (30.8)
0.656
 Men
35
25.40 ± 14.939
22 (62.9)
13 (37.1)
Women
 Case
68
27.74 ± 15.554
0.004
33 (42.3)
35 (63.6)
0.022
 Control
65
20.35 ± 13.008
45 (57.7)
20 (36.4)
Men
 Case
31
23.68 ± 14.181
0.634
17 (43.6)
14 (51.9)
0.618
 Control
35
25.40 ± 14.939
22 (56.4)
13 (48.1)
aGeneral Health Questionnaire (GHQ)
bhaving normal mental health
chaving poor mental health

Discussion

Vitiligo is an acquired disease, which is caused by the loss of functioning melanocytes, and its cause is still unknown. There are different treatment options based on different mechanisms to treat vitiligo.
Although vitiligo does not cause physical disability, long-term treatment, lack of consistent effective therapy and a significant financial burden are stressful for patients who have been involved. This issue affects the patients’ emotions, mental well-being and sexual relationship, and has a significant effect on patients’ quality of life. In reviewing DLQI studies, patients’ quality of life with vitiligo has been evaluated over the past 20 years [31]. In several studies, poor quality of life of patients was observed in some countries [32] as well as in Iran [3335]. Studies showed poorer quality of life in women with vitiligo compared to men with vitiligo [36], in married women in comparison with single women [33], and in Muslim women in comparison with Muslim men [37]. Nonetheless, depression [20, 25, 38, 39], anxiety and hopelessness [40, 41], were more reported in vitiligo patients.
In this study we investigated the hopelessness, depression, anxiety and general health levels of vitiligo patients. We found that the levels of anxiety and hopelessness in patients were significantly higher than healthy controls.
The results also showed that women with vitiligo compered to healthy controls were more anxious and hopeless while, there was no significant difference in the levels of anxiety and hopelessness among men with vitiligo in comparison with the healthy controls.
It seems that the significant difference in the levels of hopelessness and anxiety between the patients and controls was due to low significant levels of these two variables between women. Our results were consistent with the results of previous studies, which suggest women with vitiligo had poorer quality of life [33, 36, 37, 42]. However, other studies concluded that vitiligo patients suffer more from depression and anxiety [20, 3841]. On the contrary to other studies, this study showed that the women were more anxious and hopeless. The married patients with genital areas and feet involvement and the single patients with trunk involvement were significantly more depressed.
The results also showed that there was a significant difference in general health between the patients, so that the patients had a worse general health. The significant difference in the general health between the patients and the healthy controls is due to a poorer general health of women with vitiligo. The results of this study also showed that married people and singles were more hopeless and anxious than their corresponding controls, whereby the singles were also even more depressed.
Some studies showed that the quality of life of vitiligo patients was affected by stigma [43], sexual dissatisfaction [44] and lack of self-esteem [45], and patients have difficulty to find a job and consider vitiligo as a significant obstacle to get married [16]. Therefore, control or treatment of vitiligo patients requires general identification of the patient’s problems, both psychological and physical, and individual therapy. In this sense, dermatologists should evaluate the psychiatric status of women with vitiligo in addition to physical treatment. Furthermore, the interaction between the patient and the doctor is also significant. Previous studies showed the effects of psychiatric disorders, patient-physician interaction, and also evaluation of patients’ mental and physical health on their quality of life [17, 46, 47]. Papadopoulos et al. showed that counseling can help to improve self-esteem and quality of life in vitiligo patients and may even have a positive effect on the course of the disease [48]. Other studies have confirmed that it is important to identify and treat patients’ psychosocial and social factors for more positive effect on quality of life and treatment [49, 50].

Conclusion

Women suffer from vitiligo more than men and are more anxious and hopeless. The physician should consider both the physical and psychological problems especially in women in order to obtain the best possible treatment.

Acknowledgements

We would like to thank Dr. Armaghan Ashraf for her support and all the patients who participated in this project.
This study was approved by the local Ethics Committee of Shiraz University of Medical Science (EC-SUMS Number: 93–6410), Informed consent was obtained from each participants.
All authors understand that the manuscript will be freely available on the internet and may be seen by the general public

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Tarle RG, Nascimento LM, Mira MT, Castro CC. Vitiligo--part 1. An Bras Dermatol. 2014;89(3):461–70 Epub 2014/06/18. PubMed PMID: 24937821; PubMed Central PMCID: PMC4056705.CrossRef Tarle RG, Nascimento LM, Mira MT, Castro CC. Vitiligo--part 1. An Bras Dermatol. 2014;89(3):461–70 Epub 2014/06/18. PubMed PMID: 24937821; PubMed Central PMCID: PMC4056705.CrossRef
3.
Zurück zum Zitat Le Poole IC, van den Wijngaard RM, Westerhof W, Dutrieux RP, Das PK. Presence or absence of melanocytes in vitiligo lesions: an immunohistochemical investigation. J Invest Dermatol. 1993;100(6):816–22 Epub 1993/06/01. PubMed PMID: 7684427.CrossRef Le Poole IC, van den Wijngaard RM, Westerhof W, Dutrieux RP, Das PK. Presence or absence of melanocytes in vitiligo lesions: an immunohistochemical investigation. J Invest Dermatol. 1993;100(6):816–22 Epub 1993/06/01. PubMed PMID: 7684427.CrossRef
5.
Zurück zum Zitat Silverberg NB. The epidemiology of vitiligo. Curr Derm Rep. 2015;4:36–43.CrossRef Silverberg NB. The epidemiology of vitiligo. Curr Derm Rep. 2015;4:36–43.CrossRef
6.
Zurück zum Zitat Mosher DB, Fitzpatrick TB, Ortonne JP, Hori Y. Disorders of pigmentation. In: Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF, editors. Dermatology in general medicine. New York: McGraw-Hill Book Co.; 1987. p. 794–876. Mosher DB, Fitzpatrick TB, Ortonne JP, Hori Y. Disorders of pigmentation. In: Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF, editors. Dermatology in general medicine. New York: McGraw-Hill Book Co.; 1987. p. 794–876.
7.
Zurück zum Zitat Masini C, AD Vitiligo. 4th ed. In: Williams H. Birgby M, Diepgen T. Herxheimer A. Naldi L. Rzany B. editors. Evidence-based dermatology. BMJ Publishing Group. 2003. Masini C, AD Vitiligo. 4th ed. In: Williams H. Birgby M, Diepgen T. Herxheimer A. Naldi L. Rzany B. editors. Evidence-based dermatology. BMJ Publishing Group. 2003.
8.
Zurück zum Zitat Majumder PP, Nordlund JJ, Nath SK. Pattern of familial aggregation of vitiligo. Arch Dermatol. 1993;129(8):994–8 Epub 1993/08/01. PubMed PMID: 8352624.CrossRef Majumder PP, Nordlund JJ, Nath SK. Pattern of familial aggregation of vitiligo. Arch Dermatol. 1993;129(8):994–8 Epub 1993/08/01. PubMed PMID: 8352624.CrossRef
10.
Zurück zum Zitat Hahn SK, Nordlund JJ. Vitiligo. Oxford: Blackwell Science; 2000. p. 1–306.CrossRef Hahn SK, Nordlund JJ. Vitiligo. Oxford: Blackwell Science; 2000. p. 1–306.CrossRef
11.
Zurück zum Zitat Braun-Falco O, Plewig G, Wolf HH. Dermatologie und Venerologie, 4. Aufl., Depigmentierungen. Berlin, Heidelberg, New York: Springer; 1996. p. 931ff. Braun-Falco O, Plewig G, Wolf HH. Dermatologie und Venerologie, 4. Aufl., Depigmentierungen. Berlin, Heidelberg, New York: Springer; 1996. p. 931ff.
12.
Zurück zum Zitat De Gruyter W. Pschyrembel Klinisches Wörterbuch (259., neu bearbeitete Auflage). Berlin: Walter de Gruyter Gmbh & Co. KG; 2002. De Gruyter W. Pschyrembel Klinisches Wörterbuch (259., neu bearbeitete Auflage). Berlin: Walter de Gruyter Gmbh & Co. KG; 2002.
13.
Zurück zum Zitat Porter J, Beuf AH, Nordlund JJ, Lerner AB. Psychological reaction to chronic skin disorders: a study of patients with vitiligo. Gen Hosp Psychiatry. 1979;1(1):73–7 Epub 1979/04/01. PubMed PMID: 499777.CrossRef Porter J, Beuf AH, Nordlund JJ, Lerner AB. Psychological reaction to chronic skin disorders: a study of patients with vitiligo. Gen Hosp Psychiatry. 1979;1(1):73–7 Epub 1979/04/01. PubMed PMID: 499777.CrossRef
14.
Zurück zum Zitat Porter J, Beuf AH, Lerner A, Nordlund J. Response to cosmetic disfigurement: patients with vitiligo. Cutis. 1987;39(6):493–4 Epub 1987/06/01. PubMed PMID: 3608575.PubMed Porter J, Beuf AH, Lerner A, Nordlund J. Response to cosmetic disfigurement: patients with vitiligo. Cutis. 1987;39(6):493–4 Epub 1987/06/01. PubMed PMID: 3608575.PubMed
15.
Zurück zum Zitat Porter JR, Beuf AH, Lerner AB, Nordlund JJ. The effect of vitiligo on sexual relationships. J Am Acad Dermatol. 1990;22(2 Pt 1):221–2 Epub 1990/02/01. PubMed PMID: 2312803.CrossRef Porter JR, Beuf AH, Lerner AB, Nordlund JJ. The effect of vitiligo on sexual relationships. J Am Acad Dermatol. 1990;22(2 Pt 1):221–2 Epub 1990/02/01. PubMed PMID: 2312803.CrossRef
19.
Zurück zum Zitat Shenefelt PD. Psychological interventions in the management of common skin conditions. Psychol Res Behav Manag. 2010;3:51–63 Epub 2010/01/01. PubMed PMID: 22110329; PubMed Central PMCID: PMC3218765.CrossRef Shenefelt PD. Psychological interventions in the management of common skin conditions. Psychol Res Behav Manag. 2010;3:51–63 Epub 2010/01/01. PubMed PMID: 22110329; PubMed Central PMCID: PMC3218765.CrossRef
21.
Zurück zum Zitat Goldberg DP, Hillier VF. A scaled version of the general health questionnaire. Psychol Med. 1979;9(1):139–45 PubMed PMID: 424481.CrossRef Goldberg DP, Hillier VF. A scaled version of the general health questionnaire. Psychol Med. 1979;9(1):139–45 PubMed PMID: 424481.CrossRef
22.
Zurück zum Zitat Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–71 PubMed PMID: 13688369.CrossRef Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–71 PubMed PMID: 13688369.CrossRef
23.
Zurück zum Zitat Beck AT, Weissman A, Lester D, Trexler L. The measurement of pessimism: the hopelessness scale. J Consult Clin Psychol. 1974;42(6):861–5 PubMed PMID: 4436473.CrossRef Beck AT, Weissman A, Lester D, Trexler L. The measurement of pessimism: the hopelessness scale. J Consult Clin Psychol. 1974;42(6):861–5 PubMed PMID: 4436473.CrossRef
24.
Zurück zum Zitat Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56(6):893–7 PubMed PMID: 3204199.CrossRef Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56(6):893–7 PubMed PMID: 3204199.CrossRef
25.
Zurück zum Zitat Mattoo SK, Handa S, Kaur I, Gupta N, Malhotra R. Psychiatric morbidity in vitiligo and psoriasis: a comparative study from India. J Dermatol. 2001;28(8):424–32 PubMed PMID: 11560159.CrossRef Mattoo SK, Handa S, Kaur I, Gupta N, Malhotra R. Psychiatric morbidity in vitiligo and psoriasis: a comparative study from India. J Dermatol. 2001;28(8):424–32 PubMed PMID: 11560159.CrossRef
26.
Zurück zum Zitat Mattoo SK, Handa S, Kaur I, Gupta N, Malhotra R. Psychiatric morbidity in vitiligo: prevalence and correlates in India. J Eur Acad Dermatol Venereol. 2002;16(6):573–8 PubMed PMID: 12482039.CrossRef Mattoo SK, Handa S, Kaur I, Gupta N, Malhotra R. Psychiatric morbidity in vitiligo: prevalence and correlates in India. J Eur Acad Dermatol Venereol. 2002;16(6):573–8 PubMed PMID: 12482039.CrossRef
27.
Zurück zum Zitat Kruger C, Smythe JW, Spencer JD, Hasse S, Panske A, Chiuchiarelli G, et al. Significant immediate and long-term improvement in quality of life and disease coping in patients with vitiligo after group climatotherapy at the Dead Sea. Acta Derm Venereol. 2011;91(2):152–9. https://doi.org/10.2340/00015555-1037 PubMed PMID: 21240455.CrossRefPubMed Kruger C, Smythe JW, Spencer JD, Hasse S, Panske A, Chiuchiarelli G, et al. Significant immediate and long-term improvement in quality of life and disease coping in patients with vitiligo after group climatotherapy at the Dead Sea. Acta Derm Venereol. 2011;91(2):152–9. https://​doi.​org/​10.​2340/​00015555-1037 PubMed PMID: 21240455.CrossRefPubMed
28.
Zurück zum Zitat Taghavi SMR. Validity and reliability of the general health questionnaire (GHQ-28) in college students of Shiraz University. J Psycho. 2002;4(20):381–98. Taghavi SMR. Validity and reliability of the general health questionnaire (GHQ-28) in college students of Shiraz University. J Psycho. 2002;4(20):381–98.
29.
Zurück zum Zitat Goudarzi MA. The study of reliability and validity of Beck hopelessness scale in a group of Shiraz University students. J Soc Sci Hum Shiraz Univ. 2002;18.2(36):27–39. Goudarzi MA. The study of reliability and validity of Beck hopelessness scale in a group of Shiraz University students. J Soc Sci Hum Shiraz Univ. 2002;18.2(36):27–39.
30.
Zurück zum Zitat Kaviani H, Seyfourian H, Sharifi V, Ebrahimkhani N. Reliability and validity of Anxiety and Depression Hospital Scales (HADS): Iranian patients with anxiety and depression disorders. Tehran Univ Med J. 2009;67(5):379–85. Kaviani H, Seyfourian H, Sharifi V, Ebrahimkhani N. Reliability and validity of Anxiety and Depression Hospital Scales (HADS): Iranian patients with anxiety and depression disorders. Tehran Univ Med J. 2009;67(5):379–85.
31.
Zurück zum Zitat Amer AA, Gao XH. Quality of life in patients with vitiligo: an analysis of the dermatology life quality index outcome over the past two decades. Int J Dermatol. 2016;55(6):608–14.CrossRef Amer AA, Gao XH. Quality of life in patients with vitiligo: an analysis of the dermatology life quality index outcome over the past two decades. Int J Dermatol. 2016;55(6):608–14.CrossRef
33.
Zurück zum Zitat Dolatshahi M, Ghazi P, Feizy V, Hemami MR. Life quality assessment among patients with vitiligo: comparison of married and single patients in Iran. Indian J Dermatol Venereol Leprol. 2008;74(6):700 Epub 2009/01/31. PubMed PMID: 19177700.PubMed Dolatshahi M, Ghazi P, Feizy V, Hemami MR. Life quality assessment among patients with vitiligo: comparison of married and single patients in Iran. Indian J Dermatol Venereol Leprol. 2008;74(6):700 Epub 2009/01/31. PubMed PMID: 19177700.PubMed
35.
Zurück zum Zitat Mashayekhi V, Javidi Z, Kiafar B, Manteghi AA, Saadatian V, Esmaeili HA, et al. Quality of life in patients with vitiligo: a descriptive study on 83 patients attending a PUVA therapy unit in Imam Reza Hospital, Mashad. Indian J Dermatol Venereol Leprol. 2010;76(5):592. https://doi.org/10.4103/0378-6323.69097 Epub 2010/09/10. PubMed PMID: 20827019.CrossRefPubMed Mashayekhi V, Javidi Z, Kiafar B, Manteghi AA, Saadatian V, Esmaeili HA, et al. Quality of life in patients with vitiligo: a descriptive study on 83 patients attending a PUVA therapy unit in Imam Reza Hospital, Mashad. Indian J Dermatol Venereol Leprol. 2010;76(5):592. https://​doi.​org/​10.​4103/​0378-6323.​69097 Epub 2010/09/10. PubMed PMID: 20827019.CrossRefPubMed
37.
Zurück zum Zitat Borimnejad L, Parsa Yekta Z, Nikbakht-Nasrabadi A, Firooz A. Quality of life with vitiligo: comparison of male and female muslim patients in Iran. Gender Med. 2006;3(2):124–30 Epub 2006/07/25. PubMed PMID: 16860271.CrossRef Borimnejad L, Parsa Yekta Z, Nikbakht-Nasrabadi A, Firooz A. Quality of life with vitiligo: comparison of male and female muslim patients in Iran. Gender Med. 2006;3(2):124–30 Epub 2006/07/25. PubMed PMID: 16860271.CrossRef
38.
Zurück zum Zitat Al-Harbi M. Prevalence of depression in vitiligo patients. Skinmed. 2013;11(6):327–30 Epub 2014/02/13. PubMed PMID: 24517036.PubMed Al-Harbi M. Prevalence of depression in vitiligo patients. Skinmed. 2013;11(6):327–30 Epub 2014/02/13. PubMed PMID: 24517036.PubMed
40.
Zurück zum Zitat Ahmed I, Ahmed S, Nasreen S. Frequency and pattern of psychiatric disorders in patients with vitiligo. J Ayub Med Coll Abbottabad. 2007;19(3):19–21 Epub 2008/05/01. PubMed PMID: 18444584.PubMed Ahmed I, Ahmed S, Nasreen S. Frequency and pattern of psychiatric disorders in patients with vitiligo. J Ayub Med Coll Abbottabad. 2007;19(3):19–21 Epub 2008/05/01. PubMed PMID: 18444584.PubMed
42.
Zurück zum Zitat Ongenae K, Van Geel N, De Schepper S, Naeyaert JM. Effect of vitiligo on self-reported health-related quality of life. Br J Dermatol. 2005;152(6):1165–72.CrossRef Ongenae K, Van Geel N, De Schepper S, Naeyaert JM. Effect of vitiligo on self-reported health-related quality of life. Br J Dermatol. 2005;152(6):1165–72.CrossRef
43.
Zurück zum Zitat Catucci Boza J, Giongo N, Machado P, Horn R, Fabbrin A, Cestari T. Quality of life impairment in children and adults with Vitiligo: a cross-sectional study based on dermatology-specific and disease-specific quality of life instruments. Dermatology. 2016;232(5):619–25.CrossRef Catucci Boza J, Giongo N, Machado P, Horn R, Fabbrin A, Cestari T. Quality of life impairment in children and adults with Vitiligo: a cross-sectional study based on dermatology-specific and disease-specific quality of life instruments. Dermatology. 2016;232(5):619–25.CrossRef
44.
Zurück zum Zitat Sarhan D, Mohammed GF, Gomaa AH, Eyada MM. Female genital dialogues: female genital self-image, sexual dysfunction, and quality of life in patients with Vitiligo with and without genital affection. J Sex Marital Therapy. 2016;42(3):267–76.CrossRef Sarhan D, Mohammed GF, Gomaa AH, Eyada MM. Female genital dialogues: female genital self-image, sexual dysfunction, and quality of life in patients with Vitiligo with and without genital affection. J Sex Marital Therapy. 2016;42(3):267–76.CrossRef
47.
Zurück zum Zitat Silvan M. The psychological aspects of vitiligo. Cutis. 2004;73(3):163–7 Epub 2004/04/13. PubMed PMID: 15074343.PubMed Silvan M. The psychological aspects of vitiligo. Cutis. 2004;73(3):163–7 Epub 2004/04/13. PubMed PMID: 15074343.PubMed
48.
Zurück zum Zitat Papadopoulos L, Bor R, Legg C. Coping with the disfiguring effects of vitiligo: a preliminary investigation into the effects of cognitive-behavioural therapy. Brit J Med Psychol. 1999;72(Pt 3):385–96 Epub 1999/10/19. PubMed PMID: 10524722.CrossRef Papadopoulos L, Bor R, Legg C. Coping with the disfiguring effects of vitiligo: a preliminary investigation into the effects of cognitive-behavioural therapy. Brit J Med Psychol. 1999;72(Pt 3):385–96 Epub 1999/10/19. PubMed PMID: 10524722.CrossRef
49.
Zurück zum Zitat Gupta MA, Gupta AK. Psychiatric and psychological co-morbidity in patients with dermatologic disorders: epidemiology and management. Am J Clin Dermatol. 2003;4(12):833–42.CrossRef Gupta MA, Gupta AK. Psychiatric and psychological co-morbidity in patients with dermatologic disorders: epidemiology and management. Am J Clin Dermatol. 2003;4(12):833–42.CrossRef
50.
Zurück zum Zitat Parsad D, Pandhi R, Dogra S, Kanwar AJ, Kumar B. Dermatology life quality index score in vitiligo and its impact on the treatment outcome. Br J Dermatol. 2003;148(2):373–4 Epub 2003/02/18. PubMed PMID: 12588405.CrossRef Parsad D, Pandhi R, Dogra S, Kanwar AJ, Kumar B. Dermatology life quality index score in vitiligo and its impact on the treatment outcome. Br J Dermatol. 2003;148(2):373–4 Epub 2003/02/18. PubMed PMID: 12588405.CrossRef
Metadaten
Titel
Evaluating prevalence of depression, anxiety and hopelessness in patients with Vitiligo on an Iranian population
verfasst von
Nasrin Hamidizadeh
Sara Ranjbar
Ahmad Ghanizadeh
Mohammad Mahdi Parvizi
Peyman Jafari
Farhad Handjani
Publikationsdatum
01.12.2020
Verlag
BioMed Central
Erschienen in
Health and Quality of Life Outcomes / Ausgabe 1/2020
Elektronische ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-020-1278-7

Weitere Artikel der Ausgabe 1/2020

Health and Quality of Life Outcomes 1/2020 Zur Ausgabe